CYTK Quote, Financials, Valuation and Earnings

Fortrea Holdings, Inc. has a net margin of -15814.98% compared to Cytokinetics, Inc.'s net margin of -2.27%. Cytokinetics, Inc.'s return on equity of -- beat Fortrea Holdings, Inc.'s return on equity of -104.76%.

Cytokinetics, Inc. has a consensus price target of $90.39, signalling upside risk potential of 33.04%. On the other hand Fortrea Holdings, Inc. has an analysts' consensus of $16.44 which suggests that it could grow by 49.42%. Given that Fortrea Holdings, Inc. has higher upside potential than Cytokinetics, Inc., analysts believe Fortrea Holdings, Inc. is more attractive than Cytokinetics, Inc..

Cytokinetics, Inc. has a beta of 0.536, which suggesting that the stock is 46.407% less volatile than S&P 500. In comparison Fortrea Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cytokinetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortrea Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics, Inc. pays -- of its earnings as a dividend. Fortrea Holdings, Inc. pays out -- of its earnings as a dividend.

Cytokinetics, Inc. quarterly revenues are $1.9M, which are smaller than Fortrea Holdings, Inc. quarterly revenues of $701.3M. Cytokinetics, Inc.'s net income of -$306.2M is lower than Fortrea Holdings, Inc.'s net income of -$15.9M. Notably, Cytokinetics, Inc.'s price-to-earnings ratio is -- while Fortrea Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics, Inc. is 92.71x versus 0.36x for Fortrea Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -15814.98% compared to Cytokinetics, Inc.'s net margin of -82.06%. Cytokinetics, Inc.'s return on equity of -- beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Cytokinetics, Inc. has a consensus price target of $90.39, signalling upside risk potential of 33.04%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.63 which suggests that it could grow by 10.19%. Given that Cytokinetics, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Cytokinetics, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Cytokinetics, Inc. has a beta of 0.536, which suggesting that the stock is 46.407% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

Cytokinetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cytokinetics, Inc. quarterly revenues are $1.9M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Cytokinetics, Inc.'s net income of -$306.2M is lower than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Cytokinetics, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics, Inc. is 92.71x versus 14.16x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lifecore Biomedical, Inc. has a net margin of -15814.98% compared to Cytokinetics, Inc.'s net margin of -32.12%. Cytokinetics, Inc.'s return on equity of -- beat Lifecore Biomedical, Inc.'s return on equity of -70.33%.

Cytokinetics, Inc. has a consensus price target of $90.39, signalling upside risk potential of 33.04%. On the other hand Lifecore Biomedical, Inc. has an analysts' consensus of $9.25 which suggests that it could grow by 29.73%. Given that Cytokinetics, Inc. has higher upside potential than Lifecore Biomedical, Inc., analysts believe Cytokinetics, Inc. is more attractive than Lifecore Biomedical, Inc..

Cytokinetics, Inc. has a beta of 0.536, which suggesting that the stock is 46.407% less volatile than S&P 500. In comparison Lifecore Biomedical, Inc. has a beta of 0.589, suggesting its less volatile than the S&P 500 by 41.122%.

Cytokinetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifecore Biomedical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics, Inc. pays -- of its earnings as a dividend. Lifecore Biomedical, Inc. pays out -- of its earnings as a dividend.

Cytokinetics, Inc. quarterly revenues are $1.9M, which are smaller than Lifecore Biomedical, Inc. quarterly revenues of $31.1M. Cytokinetics, Inc.'s net income of -$306.2M is lower than Lifecore Biomedical, Inc.'s net income of -$10M. Notably, Cytokinetics, Inc.'s price-to-earnings ratio is -- while Lifecore Biomedical, Inc.'s PE ratio is 133.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics, Inc. is 92.71x versus 1.92x for Lifecore Biomedical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare, Inc. has a net margin of -15814.98% compared to Cytokinetics, Inc.'s net margin of -1.41%. Cytokinetics, Inc.'s return on equity of -- beat Molina Healthcare, Inc.'s return on equity of 10.89%.

Cytokinetics, Inc. has a consensus price target of $90.39, signalling upside risk potential of 33.04%. On the other hand Molina Healthcare, Inc. has an analysts' consensus of $157.56 which suggests that it could grow by 4.35%. Given that Cytokinetics, Inc. has higher upside potential than Molina Healthcare, Inc., analysts believe Cytokinetics, Inc. is more attractive than Molina Healthcare, Inc..

Cytokinetics, Inc. has a beta of 0.536, which suggesting that the stock is 46.407% less volatile than S&P 500. In comparison Molina Healthcare, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.546%.

Cytokinetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics, Inc. pays -- of its earnings as a dividend. Molina Healthcare, Inc. pays out -- of its earnings as a dividend.

Cytokinetics, Inc. quarterly revenues are $1.9M, which are smaller than Molina Healthcare, Inc. quarterly revenues of $11.4B. Cytokinetics, Inc.'s net income of -$306.2M is lower than Molina Healthcare, Inc.'s net income of -$160M. Notably, Cytokinetics, Inc.'s price-to-earnings ratio is -- while Molina Healthcare, Inc.'s PE ratio is 17.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics, Inc. is 92.71x versus 0.18x for Molina Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.